Safety and immunogenicity of the modified adult tick-borne encephalitis vaccine FSME-IMMUN®: Results of two large phase 3 clinical studies

Vaccine

Volumn 24, Issue 24, 2006, Pages 5256-5263

  Loew Baselli, A ^a   Konior, R ^b   Pavlova, B G ^a   Fritsch, S ^a   Poellabauer, E ^a   Maritsch, F ^a   Harmacek, P ^a   Krammer, M ^a   Barrett, P N ^a   Ehrlich, H J ^a  

^a BAXTER BIOSCIENCE   (Austria)

^b Krakowski Szpital Specjalistyczny Im Jana Pawła II   (Poland)

Author keywords

FSME IMMUN vaccine; Phase 3 clinical studies; Tick borne encephalitis

Indexed keywords

FSME IMMUN; TICK BORNE ENCEPHALITIS VACCINE;

ADOLESCENT; ADULT; AGED; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HUMAN; IMMUNOGENICITY; INJECTION SITE PAIN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; MYALGIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SINGLE BLIND PROCEDURE; TICK BORNE ENCEPHALITIS; VIRUS NEUTRALIZATION;

ADOLESCENT; ADULT; AGED; ANTIBODIES, VIRAL; ENCEPHALITIS VIRUSES, TICK-BORNE; FEMALE; HUMANS; MALE; MIDDLE AGED; SINGLE-BLIND METHOD; VACCINATION; VIRAL VACCINES;

EID: 33744819743     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.03.061     Document Type: Article

References (14)

1. Barrett P.N., Schober-Bendixen S., and Ehrlich H.J. History of TBE vaccines. Vaccine 21 1 (2003) 41-49
2. Haglund M., and Gunther G. Tick-borne encephalitis--pathogenesis, clinical course and long-term follow-up. Vaccine 21 1 (2003) 11-18
3. Heinz F.X., and Kunz C. Tick-borne encephalitis and the impact of vaccination. Arch Virol 18 (2004) 201-205
4. Kunz C. TBE vaccination and the Austrian experience. Vaccine 21 1 (2003) 50-55
5. Ehrlich H.J., Pavlova B.G., Fritsch S., Poellabauer E.M., Loew-Baselli A., Obermann-Slupetzky O., et al. Randomized, phase 2 dose-finding studies of a modified tick-borne encephalitis vaccine: evaluation of safety and immunogenicity. Vaccine 22 2 (2003) 217-223
6. Barrett P.N., Dorner F., Ehrlich H.J., and Plotkin S.A. Tick-borne encephalitis virus vaccine. In: Plotkin S.A., and Orenstein W.A. (Eds). Vaccines (2004), Saunders & Elsevier, Philadelphia 1039-1055
7. Bock H.L., Klockmann U., Jungst C., Schindel-Kunzel F., Theobald K., and Zerban R. A new vaccine against tick-borne encephalitis: initial trial in man including a dose-response study. Vaccine 8 1 (1990) 22-24
8. Harabacz I., Bock H., Jungst C., Klockmann U., Praus M., and Weber R. A randomized phase 2 study of a new tick-borne encephalitis vaccine using three different doses and two immunization regimens. Vaccine 10 3 (1992) 145-150
9. Kießig S.T., Abler U., Risse P., Friedrich J., Heinz F., and Kunz C. Problems of cut-off level determination in enzyme immunoassays: the case of TBE-ELISA. Klin Lab 39 (1993) 877-886
10. Adner N., Leibl H., Enzersberger O., Kirgios M., and Wahlberg T. Pharmacokinetics of human tick-borne encephalitis virus antibody levels after injection with human tick-borne encephalitis immunoglobulin, solvent/detergent treated, FSME-BULIN S/D in healthy volunteers. Scand J Infect Dis 33 (2001) 843-847
11. Common Toxicity Criteria, Version 2.0, April 30, 1999. http://ctep.cancer.gov/forms/CTCv20_4-30-992.pdf, April 18, 2005.
12. Chan I.S.F., and Zhang Z. Test based exact confidence intervals for the difference of two binominal proportions. Biometrics 55 (1999) 1201-1209
13. Zent O., Beran J., Jilg W., Mach T., and Banzhoff A. Clinical evaluation of a polygeline-free tick-borne encephalitis vaccine for adolescents and adults. Vaccine 21 7-8 (2003) 738-741
14. Clement J., Van Ranst M., and Leirs H. The results of tick-bone encephalitis (TBE)-vaccination. Am J Trop Med Hyg 62 3 (2000) 325-326